HedgeChatter

  • Home /
  • Tag Archives

HPTX

9:05 am Hyperion Therapeutics announces the publication of phase 2 results of Glycerol Phenylbutyrate for the treatment of hepatic encephalopathy in hepatology; study met its primary endpoint; data show significant reduction in he events an

moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on 9:05 am Hyperion Therapeutics announces the publication of phase 2 results of Glycerol Phenylbutyrate for the treatment of hepatic encephalopathy in hepatology; study met its primary endpoint; data show significant reduction in he events an read more

Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology

[GlobeNewswire] – BRISBANE, Calif. — Hyperion Therapeutics, Inc. today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology read more

Hyperion Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results After Market on February 27, 2014

[GlobeNewswire] – BRISBANE, Calif. — Hyperion Therapeutics, Inc. today announced that it will report fourth quarter and full year 2013 financial results after market closes on Thursday, February 27, 2014. Hyperion will … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

February 24, 2014 Bystocknews , Comments Off on Hyperion Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results After Market on February 27, 2014 read more

Hyperion Therapeutics Issued Key Patent Pertaining to Use of Fasting Ammonia

[at noodls] – SOUTH SAN FRANCISCO, Calif., April 16, 2013 (GLOBE NEWSWIRE) — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Patent & Trademark Office (USPTO) has issued to Hyperion U.S. patent … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

April 16, 2013 Bystocknews , Comments Off on Hyperion Therapeutics Issued Key Patent Pertaining to Use of Fasting Ammonia read more

Hyperion Therapeutics Announces Pricing of Follow-On Offering

[at noodls] – SOUTH SAN FRANCISCO, Calif., March 8, 2013 (GLOBE NEWSWIRE) — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today the pricing of its follow-on offering of 2,875,000 shares of its common stock at … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

March 8, 2013 Bystocknews , Comments Off on Hyperion Therapeutics Announces Pricing of Follow-On Offering read more

Hyperion Makes RAVICTI(TM) Available for Shipment to UCD Patients

[at noodls] – SOUTH SAN FRANCISCO, Calif., Feb. 28, 2013 (GLOBE NEWSWIRE) — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that RAVICTIâ„¢ (glycerol phenylbutyrate) Liquid is now available for shipment to … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

February 28, 2013 Bystocknews , Comments Off on Hyperion Makes RAVICTI(TM) Available for Shipment to UCD Patients read more

Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results

[at noodls] – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2013 (GLOBE NEWSWIRE) — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported financial operating results for the fourth quarter and the year ended December 31, … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

February 25, 2013 Bystocknews , Comments Off on Hyperion Therapeutics Announces Fourth Quarter and Full Year 2012 Operating Results read more

Hyperion Therapeutics to Present at the Leerink Swann Global Healthcare Conference

[at noodls] – SOUTH SAN FRANCISCO, Calif., Feb. 8, 2013 (GLOBE NEWSWIRE) — Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Leerink Swann Global Healthcare Conference … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

February 8, 2013 Bystocknews , Comments Off on Hyperion Therapeutics to Present at the Leerink Swann Global Healthcare Conference read more

Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders

[at noodls] – Anticipated market launch by end of April 2013 Patent allowance extends coverage to 2032 SOUTH SAN FRANCISCO, Calif., Feb. 1, 2013 (GLOBE NEWSWIRE) — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced … moreView todays social media effects on HPTXView the latest stocks trending across Twitter. Click to view dashboardSee who Hyperion is hiring next, click here to view […]

February 1, 2013 Bystocknews , Comments Off on Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders read more